Condition: Leiomyosarcoma
Intervention: Other: Blood and Tissue collection
Sponsor: Sarcoma Alliance for Research through Collaboration
Recruiting
Feeds
20859 items (20859 unread) in 74 feeds
Acinar Cell Carcinoma
(201 unread)
Acinic Cell Carcinoma
(104 unread)
Adenoid Cystic Carcinoma
(367 unread)
Adrenal Gland Cancer
(1718 unread)
Ampulla Of Vater
(213 unread)
Anal Cancer
(1799 unread)
Angiosarcoma
(359 unread)
Appendix Cancer
(450 unread)
Bile Duct Cancer
(2698 unread)
Brain and CNS
(2597 unread)
Carcinoid
(671 unread)
Endocrine/Neuroendocrine
(2404 unread)
Gall Bladder Cancer
(1146 unread)
Hemangioendothelioma
(506 unread)
Hepatoblastoma
(366 unread)
Pancreas
(416 unread)
Phyllodes
(215 unread)
PMP and Mucinous Tumors
(242 unread)
Rhabdomyosarcoma
(772 unread)
Sarcoma
(3615 unread)
Trial - Sarcoma (100 unread)
-
Localized Leiomyosarcoma Biomarker Protocol
Posted: June 14th, 2021, 2:00pm GMT
-
Exercise and Soft Tissue Sarcoma
Posted: June 10th, 2021, 2:00pm GMT
Condition: Soft Tissue Sarcoma
Intervention: Other: neoadjuvant exercise therapy
Sponsors: Duke University; University of North Carolina, Chapel Hill
Recruiting -
APL-2 and Pembrolizumab Versus APL-2, Pembrolizumab and Bevacizumab Versus Bevacizumab Alone for the Treatment of Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer and Malignant Effusion
Posted: June 9th, 2021, 2:00pm GMT
Conditions: Fallopian Tube Carcinosarcoma; Fallopian Tube Clear Cell Adenocarcinoma; Fallopian Tube Endometrioid Adenocarcinoma; Fallopian Tube Serous Adenocarcinoma; Ovarian Carcinosarcoma; Ovarian Clear Cell Adenocarcinoma; Ovarian Endometrioid Adenocarcinoma; Ovarian Serous Adenocarcinoma; Primary Peritoneal Carcinosarcoma; Primary Peritoneal Clear Cell Adenocarcinoma; Primary Peritoneal Endometrioid Adenocarcinoma; Primary Peritoneal Serous Adenocarcinoma; Recurrent Fallopian Tube Carcinoma; Recurrent Ovarian Carcinoma; Recurrent Primary Peritoneal Carcinoma
Interventions: Biological: Bevacizumab; Drug: Pegcetacoplan; Biological: Pembrolizumab; Other: Quality-of-Life Assessment; Other: Questionnaire Administration
Sponsor: Roswell Park Cancer Institute
Not yet recruiting -
Tazemetostat in Malignant Peripheral Nerve Sheath Tumors
Posted: June 8th, 2021, 2:00pm GMT
Condition: Peripheral Nerve Sheath Tumor
Intervention: Drug: Tazemetostat
Sponsors: University of Florida; Epizyme, Inc.
Not yet recruiting -
Functional Muscle Transfers in Lower Limb Sarcoma: 3D Gait Analysis and Environmental Simulation
Posted: June 3rd, 2021, 2:00pm GMT
Conditions: Sarcoma; Muscle Tumor; Muscle Loss
Intervention: Procedure: Functional muscle transfer
Sponsors: NHS Greater Glasgow and Clyde; University of Strathclyde
Recruiting -
Camrelizumab Plus Doxorubicin for the First Line Treatment of Adcanced Soft Tissue Sarcoma
Posted: June 2nd, 2021, 2:00pm GMT
Conditions: Soft Tissue Sarcoma; Neoplasms, Connective and Soft Tissue; Sarcoma Metastatic; Sarcoma,Soft Tissue
Interventions: Drug: Camrelizumab; Drug: Adriamycin
Sponsor: Wuhan Union Hospital, China
Recruiting -
9-ING-41Combined With Chemotherapy in Adolescents and Adults
Posted: May 28th, 2021, 2:00pm GMT
Conditions: Sarcoma; Soft Tissue Sarcoma; Metastatic Sarcoma; Undifferentiated Pleomorphic Sarcoma; Myxofibrosarcoma; Leiomyosarcoma; Liposarcoma; Angiosarcoma; Synovial Sarcoma; Rhabdomyosarcoma; Spindle Cell Sarcoma; High Grade Sarcoma; Bone Sarcoma
Interventions: Drug: Gemcitabine; Drug: Docetaxel; Drug: 9-ING-41
Sponsors: Brown University; Actuate Therapeutics Inc.
Not yet recruiting -
Tislelizumab for the Treatment of Recurrent Mismatch Repair Deficient Endometrial Cancer
Posted: May 28th, 2021, 2:00pm GMT
Conditions: Lynch Syndrome; Recurrent Endometrial Carcinoma; Recurrent Endometrial Clear Cell Adenocarcinoma; Recurrent Uterine Corpus Carcinosarcoma; Mismatch Repair Deficiency; Recurrent Endometrial Cancer; Metastatic Endometrial Cancer
Interventions: Procedure: Biopsy; Drug: Carboplatin; Drug: Paclitaxel; Biological: Tislelizumab
Sponsor: Floor Backes
Not yet recruiting -
Defendor Special: A Multicenter Prospective Observational Post-registration Study of Combined Chemotherapy With Empegfilrastim Support to Evaluate Safety and Efficacy in Patients With High and "Gray Zone" Risk Reccurrence Breast Cancer, Gastointestinal
Posted: May 27th, 2021, 2:00pm GMT
Conditions: Solid Tumor; High-Risk Cancer; Breast Cancer; Gastrointestinal Cancer; Gynecological Malignancies; Myelosuppression
Intervention: Drug: Empegfilgrastim
Sponsor: Moscow Clinical Scientific Center
Recruiting -
Pomalidomide and Nivolumab in People With Virus-Associated Malignancies With or Without HIV
Posted: May 26th, 2021, 2:00pm GMT
Conditions: Viral Associated Malignancies; Kaposi Sarcoma; EBV/KSHV-associated Lymphomas
Interventions: Drug: Pomalidomide; Drug: Nivolumab
Sponsor: National Cancer Institute (NCI)
Not yet recruiting -
Study of PBI-200 in Subjects With NTRK-Fusion-Positive Solid Tumors
Posted: May 26th, 2021, 2:00pm GMT
Conditions: Solid Tumor, Adult; Brain Tumor, Primary; Desmoplastic Small Round Cell Tumor
Intervention: Drug: PBI-200
Sponsor: Pyramid Biosciences
Not yet recruiting -
A Study of Mitoxantrone Hydrochloride Liposome Injection in Subjects With Advanced Bone and Soft Tissue Sarcoma
Posted: May 25th, 2021, 2:00pm GMT
Condition: Unresectable or Metastatic Bone and Soft Tissue Sarcoma
Intervention: Drug: Mitoxantrone Hydrochloride Liposome Injection
Sponsor: CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Not yet recruiting -
Study of Onivyde With Talazoparib or Temozolomide in Children With Recurrent Solid Tumors and Ewing Sarcoma
Posted: May 25th, 2021, 2:00pm GMT
Conditions: Recurrent Solid Tumor; Recurrent Ewing Sarcoma; Recurrent Hepatoblastoma; Recurrent Malignant Germ Cell Tumor; Recurrent Malignant Solid Neoplasm; Recurrent Neuroblastoma; Recurrent Osteosarcoma; Recurrent Peripheral Primitive Neuroectodermal Tumor; Recurrent Rhabdoid Tumor; Recurrent Rhabdomyosarcoma; Recurrent Soft Tissue Sarcoma; Recurrent Wilms Tumor; Refractory Ewing Sarcoma; Refractory Hepatoblastoma; Refractory Malignant Germ Cell Tumor; Refractory Malignant Solid Neoplasm; Refractory Neuroblastoma; Refractory Osteosarcoma; Refractory Peripheral Primitive Neuroectodermal Tumor; Refractory Rhabdoid Tumor; Refractory Rhabdomyosarcoma; Refractory Soft Tissue Sarcoma
Interventions: Drug: Onivyde; Drug: Talazoparib; Drug: Temozolomide
Sponsors: St. Jude Children's Research Hospital; Pfizer; Ipsen
Recruiting -
B7-H3-Specific Chimeric Antigen Receptor Autologous T-Cell Therapy for Pediatric Patients With Solid Tumors (3CAR)
Posted: May 21st, 2021, 2:00pm GMT
Conditions: Pediatric Solid Tumor; Osteosarcoma; Rhabdomyosarcoma; Neuroblastoma; Ewing Sarcoma; Wilms Tumor; Adrenocortical Cancer; Desmoplastic Small Round Cell Tumor; Germ Cell Cancer; Rhabdoid Tumor; Clear Cell Sarcoma; Hepatoblastoma; Melanoma; Carcinoma; Malignant Peripheral Nerve Sheath Tumors; Soft Tissue Sarcoma
Interventions: Drug: Fludarabine; Drug: Cyclophosphamide; Drug: MESNA; Drug: B7-H3 CAR T cells
Sponsor: St. Jude Children's Research Hospital
Not yet recruiting -
NT-I7 for Kaposi Sarcoma in Patients With or Without HIV
Posted: May 19th, 2021, 2:00pm GMT
Conditions: AIDS-Related Kaposi Sarcoma; HIV Infection; Kaposi Sarcoma
Intervention: Biological: Efineptakin alfa
Sponsors: Fred Hutchinson Cancer Research Center; Cancer Immunotherapy Trials Network
Not yet recruiting -
Phase 1/2 Study of Vincristine and Temozolomide in Combination With PEN-866 for Adolescents and Young Adults With Relapsed or Refractory Solid Tumors
Posted: May 18th, 2021, 2:00pm GMT
Conditions: Sarcoma, Ewing; Rhabdomyosarcoma
Interventions: Drug: PEN-866; Drug: Vincristine; Drug: Temozolomide
Sponsor: National Cancer Institute (NCI)
Not yet recruiting -
Observational Study in Localized Osteosarcoma
Posted: May 18th, 2021, 2:00pm GMT
Condition: Localized Osteosarcoma
Intervention: Other: Treatment of Osteosarcoma according the AIEOP/ISG OS 2021 recommendations (includes drugs, surgery, radiotherapy or any other received treatments)
Sponsors: Italian Sarcoma Group; Associazione Italiana Ematologia Oncologia Pediatrica
Not yet recruiting -
Phase 0 Australia Master Protocol for CIVO Intratumoural Microdosing of Anti-Cancer Therapies
Posted: May 18th, 2021, 2:00pm GMT
Condition: Solid Tumour
Interventions: Biological: MVC-101; Biological: Nivolumab; Combination Product: MVC-101 + Nivolumab
Sponsors: Presage Biosciences; Maverick Therapeutics, Inc
Not yet recruiting -
Hyperthermia Enhanced Re-irradiation of Loco-regional Recurrent Tumors
Posted: May 17th, 2021, 2:00pm GMT
Conditions: Recurrent Cancer; Prostate Cancer; Cervical Cancer; Anal Cancer; Sarcoma; Rectal Cancer; Neuroendocrine Tumors; Esophageal Cancer; Pancreas Cancer; Squamous Cell Carcinoma
Intervention: Device: loco-regional hyperthermia
Sponsor: Charite University, Berlin, Germany
Recruiting -
Study of Liposomal Annamycin for the Treatment of Subjects With Soft-Tissue Sarcomas (STS) With Pulmonary Metastases
Posted: May 14th, 2021, 2:00pm GMT
Conditions: Sarcoma,Soft Tissue; Pulmonary Metastasis
Intervention: Drug: Liposomal Annamycin (L-Annamycin)
Sponsor: Moleculin Biotech, Inc.
Recruiting -
A Study to Evaluate the Safety and Efficacy of ALMB-0168 in Patients With Osteosarcoma
Posted: May 14th, 2021, 2:00pm GMT
Condition: Osteosarcoma
Intervention: Drug: ALMB-0168
Sponsors: AlaMab Therapeutics (Shanghai) Inc.; CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Not yet recruiting -
RegoNivo vs Standard of Care Chemotherapy in AGOC
Posted: May 10th, 2021, 2:00pm GMT
Condition: Gastro-Oesophageal Cancer
Interventions: Drug: Regorafenib; Biological: Nivolumab; Drug: Docetaxel; Drug: Paclitaxel; Drug: Irinotecan; Drug: Trifluridine/Tipracil
Sponsors: Australasian Gastro-Intestinal Trials Group; Bayer; Bristol-Myers Squibb; University of Sydney; Academic and Community Cancer Research United; Taiwanese Cooperative Oncology Group; Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest; Canadian Cancer Trials Group
Not yet recruiting -
Gemcitabine With Ascorbate Including Adolescents
Posted: May 7th, 2021, 2:00pm GMT
Conditions: Soft Tissue Sarcoma; Bone Sarcoma; Unresectable Soft Tissue Sarcoma; Metastatic Bone Sarcoma; Metastatic Soft-tissue Sarcoma; Unresectable Bone Sarcoma
Interventions: Drug: Ascorbate; Drug: Gemcitabine
Sponsor: William Terry
Not yet recruiting -
Bintrafusp Alfa and Doxorubicin Hydrochloride in Treating Patients With Advanced Sarcoma
Posted: May 5th, 2021, 2:00pm GMT
Conditions: Advanced Soft-tissue Sarcoma; Metastatic Soft-tissue Sarcoma
Interventions: Drug: Bintrafusp alfa; Drug: Doxorubicin
Sponsors: Institut Bergonié; Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany
Not yet recruiting -
Cemiplimab for Secondary Angiosarcomas
Posted: May 5th, 2021, 2:00pm GMT
Conditions: Secondary Angiosarcoma; Locally Advanced Sarcoma; Metastasis
Intervention: Drug: Cemiplimab
Sponsors: Radboud University; Genzyme Europe B.V.
Not yet recruiting -
A Study of ASTX727 in People With Malignant Peripheral Nerve Sheath Tumors (MPNST)
Posted: May 4th, 2021, 2:00pm GMT
Condition: Malignant Peripheral Nerve Sheath Tumors (MPNST)
Intervention: Drug: ASTX727
Sponsors: Memorial Sloan Kettering Cancer Center; Astex Pharmaceuticals, Inc.
Recruiting -
CBL0137 for the Treatment of Relapsed or Refractory Solid Tumors, Including CNS Tumors and Lymphoma
Posted: May 4th, 2021, 2:00pm GMT
Conditions: Diffuse Midline Glioma, H3 K27M-Mutant; Metastatic Malignant Neoplasm in the Central Nervous System; Recurrent Diffuse Intrinsic Pontine Glioma; Recurrent Lymphoma; Recurrent Malignant Solid Neoplasm; Recurrent Osteosarcoma; Recurrent Primary Malignant Central Nervous System Neoplasm; Refractory Lymphoma; Refractory Malignant Solid Neoplasm; Refractory Osteosarcoma; Refractory Primary Malignant Central Nervous System Neoplasm
Intervention: Drug: FACT Complex-targeting Curaxin CBL0137
Sponsor: Children's Oncology Group
Not yet recruiting -
Neutrophils in Bone Sarcomas
Posted: April 30th, 2021, 2:00pm GMT
Condition: Osteosarcoma, Chondrosarcoma
Intervention: Other: No intervention
Sponsor: Université de Reims Champagne-Ardenne
Recruiting -
Clinical Study of CD276 Targeted Autologous Chimeric Antigen Receptor T Cell Infusion in Patients With CD276 Positive Advanced Solid Tumor
Posted: April 29th, 2021, 2:00pm GMT
Conditions: Osteosarcoma; Neuroblastoma; Gastric Cancer; Lung Cancer
Intervention: Drug: Targeting CD276 CAR T cells
Sponsors: PersonGen BioTherapeutics (Suzhou) Co., Ltd.; The First Affiliated Hospital of Zhengzhou University
Not yet recruiting -
Safely Stopping Pre-medications in Patients With Breast Cancer Who Are Receiving Paclitaxel
Posted: April 28th, 2021, 2:00pm GMT
Conditions: Anatomic Stage 0 Breast Cancer AJCC v8; Anatomic Stage I Breast Cancer AJCC v8; Anatomic Stage IA Breast Cancer AJCC v8; Anatomic Stage IB Breast Cancer AJCC v8; Anatomic Stage II Breast Cancer AJCC v8; Anatomic Stage IIA Breast Cancer AJCC v8; Anatomic Stage IIB Breast Cancer AJCC v8; Anatomic Stage III Breast Cancer AJCC v8; Anatomic Stage IIIA Breast Cancer AJCC v8; Anatomic Stage IIIB Breast Cancer AJCC v8; Anatomic Stage IIIC Breast Cancer AJCC v8; Anatomic Stage IV Breast Cancer AJCC v8; Breast Carcinoma; Prognostic Stage 0 Breast Cancer AJCC v8; Prognostic Stage I Breast Cancer AJCC v8; Prognostic Stage IA Breast Cancer AJCC v8; Prognostic Stage IB Breast Cancer AJCC v8; Prognostic Stage II Breast Cancer AJCC v8; Prognostic Stage IIA Breast Cancer AJCC v8; Prognostic Stage IIB Breast Cancer AJCC v8; Prognostic Stage III Breast Cancer AJCC v8; Prognostic Stage IIIA Breast Cancer AJCC v8; Prognostic Stage IIIB Breast Cancer AJCC v8; Prognostic Stage IIIC Breast Cancer AJCC v8; Prognostic Stage IV Breast Cancer AJCC v8
Interventions: Drug: Cimetidine; Drug: Dexamethasone; Drug: Diphenhydramine; Drug: Famotidine; Drug: Paclitaxel; Other: Quality-of-Life Assessment; Drug: Ranitidine
Sponsor: Ohio State University Comprehensive Cancer Center
Not yet recruiting -
Tomosymthesis for Breast Mass Lesion Characterization
Posted: April 28th, 2021, 2:00pm GMT
Condition: Female Breast Cancer
Intervention:
Sponsors: Asmaa Abdelmonem Ahmed; Assiut University
Not yet recruiting -
IBI188 Combination Therapy in Solid Tumors
Posted: April 27th, 2021, 2:00pm GMT
Conditions: Solid Tumors; Lung Adenocarcinoma; Osteosarcoma
Interventions: Drug: IBI188; Drug: GM-CSF; Drug: Cisplatin/Carboplatin; Drug: Bevacizumab; Drug: Sintilimab; Drug: Pemetrexed
Sponsor: Innovent Biologics (Suzhou) Co. Ltd.
Not yet recruiting -
Albumin-bound Paclitaxel Combined With Liposomal Doxorubicin in the Treatment of Advanced or Unresectable Angiosarcoma
Posted: April 26th, 2021, 2:00pm GMT
Condition: Angiosarcoma Metastatic
Intervention: Drug: Abraxane combined with liposomal doxorubicin
Sponsor: Sun Yat-sen University
Not yet recruiting -
Indo-cyanine Green (ICG) in Paediatric Oncology MIS
Posted: April 22nd, 2021, 2:00pm GMT
Conditions: Pediatric Renal Tumor; Metastatic Osteosarcoma; Metastatic Ewing Sarcoma; Pulmonary Metastasis; Rhabdomyosarcoma; Non-Rhabdo. Soft Tissue Sarcoma
Intervention: Drug: Indocyanine green
Sponsor: Birmingham Women's and Children's NHS Foundation Trust
Not yet recruiting -
A Study of ELI-002 in Subjects With KRAS Mutated Pancreatic Ductal Adenocarcinoma (PDAC) and Other Solid Tumor
Posted: April 21st, 2021, 2:00pm GMT
Conditions: Minimal Residual Disease; KRAS G12D; KRAS G12R; NRAS G12D; NRAS G12R; Pancreatic Ductal Adenocarcinoma; Colorectal Cancer; Non-small Cell Lung Cancer; Ovarian Cancer; Cholangiocarcinoma; Bile Duct Cancer; Gallbladder Carcinoma
Interventions: Drug: ELI-002 (Dose Escalation); Drug: ELI-002 (at the RP2D); Other: Observation
Sponsor: Elicio Therapeutics
Recruiting -
Minimal Residual Disease: A Trial Using Liquid Biopsies in Solid Malignancies.
Posted: April 21st, 2021, 2:00pm GMT
Condition: Cancer
Intervention:
Sponsor: University of Leicester
Recruiting -
Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors
Posted: April 20th, 2021, 2:00pm GMT
Conditions: Colorectal Carcinoma; Endometrial Carcinoma; Melanoma; Neuroblastoma; Ovarian Carcinoma; Pancreatic Ductal Adenocarcinoma; Recurrent Desmoid Fibromatosis; Recurrent Ewing Sarcoma; Recurrent Hepatoblastoma; Recurrent Hepatocellular Carcinoma; Recurrent Malignant Solid Neoplasm; Recurrent Non-Hodgkin Lymphoma; Recurrent Osteosarcoma; Refractory Desmoid Fibromatosis; Refractory Ewing Sarcoma; Refractory Hepatoblastoma; Refractory Hepatocellular Carcinoma; Refractory Malignant Solid Neoplasm; Refractory Non-Hodgkin Lymphoma; Refractory Osteosarcoma; Solid Pseudopapillary Neoplasm of the Pancreas; Wilms Tumor
Intervention: Drug: Tegavivint
Sponsor: Children's Oncology Group
Not yet recruiting -
Observational Study on Skeletal Ewing's Sarcoma
Posted: April 15th, 2021, 2:00pm GMT
Condition: Ewing Sarcoma of Bone
Intervention: Other: Treatment of Ewings Sarcoma of bone according clinical practice (includes drugs, surgery, radiotherapy or any other received treatments)
Sponsor: Italian Sarcoma Group
Recruiting -
Efficacy and Safety of Anlotinib, Irinotecan and Temozolomide in the Treatment of Refractory or Recurrent Neuroblastoma in Children: an Open, Single Arm, Single Center, Phase II Clinical Study
Posted: April 13th, 2021, 2:00pm GMT
Condition: Refractory or Recurrent Neuroblastoma in Children
Intervention: Drug: Anlotinib and irinotecan combined with temozolomide
Sponsors: Tianjin Medical University Cancer Institute and Hospital; Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Not yet recruiting -
A Study of PRT1419 in Patients With Advanced Solid Tumors
Posted: April 8th, 2021, 2:00pm GMT
Conditions: Sarcoma; Melanoma; Lung Cancer; Breast Cancer
Intervention: Drug: PRT1419
Sponsor: Prelude Therapeutics
Not yet recruiting -
A Study to Find a Safe and Effective Dose of BI 1701963 Alone and in Combination With BI 3011441 in Patients With Advanced Cancer and a Certain Mutation (Kirsten Rat Sarcoma Viral Oncogene Homologue [KRAS])
Posted: April 8th, 2021, 2:00pm GMT
Condition: Solid Tumors, KRAS Mutation
Interventions: Drug: BI 1701963; Drug: BI 3011441
Sponsor: Boehringer Ingelheim
Recruiting -
A Study of ZN-c3 in Combination With Gemcitabine in Subjects With Osteosarcoma
Posted: April 6th, 2021, 2:00pm GMT
Condition: Osteosarcoma
Interventions: Drug: ZN-c3; Drug: Gemcitabine
Sponsor: K-Group Beta
Not yet recruiting -
Image Assisted Optimization of Proton Radiation Therapy in Chordomas and Chondrosarcomas
Posted: April 6th, 2021, 2:00pm GMT
Conditions: Bone Neoplasm of Vertebral Column; Chordoma; Chondrosarcoma; Magnetic Resonance Imaging; PET-CT; Proton Therapy
Intervention:
Sponsors: Leiden University Medical Center; HollandPTC; Varian Medical Systems
Recruiting -
Apatinib Plus IE Chemotherapy (Ifosfamide and Etoposide) for Relapsed or Refractory Osteosarcoma
Posted: April 1st, 2021, 2:00pm GMT
Conditions: Effect of Drug; Toxicity, Drug
Intervention: Drug: apatinib
Sponsors: Peking University People's Hospital; Peking University Shougang Hospital; Jiangsu HengRui Medicine Co.
Recruiting -
A Study of Different Dosing Schedules of Selinexor in Sarcoma Patients
Posted: March 23rd, 2021, 2:00pm GMT
Conditions: Soft Tissue Sarcoma; Malignant Peripheral Nerve Sheath Tumor (MPNST); Leiomyosarcoma; Endometrial Stromal Sarcoma
Intervention: Drug: Selinexor
Sponsor: University Health Network, Toronto
Recruiting -
Targeting ATR in Soft-tissue Sarcomas
Posted: March 19th, 2021, 2:00pm GMT
Condition: Leiomyosarcoma, Adult
Interventions: Drug: Association of berzosertib with gemcitabine; Drug: Gemcitabine
Sponsors: Institut Bergonié; Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany
Not yet recruiting -
Real-world Treatment Patterns and Associated Outcomes in Patients With Resectable Early-stage Non-small Cell Lung Cancer
Posted: March 19th, 2021, 2:00pm GMT
Condition: Non-small Cell Lung Cancer
Intervention:
Sponsor: AstraZeneca
Not yet recruiting -
SARC038: Phase 2 Study of Regorafenib and Nivolumab in Osteosarcoma
Posted: March 18th, 2021, 2:00pm GMT
Conditions: Osteosarcoma; Osteosarcoma in Children; Osteosarcoma Recurrent; Osteosarcoma Metastatic
Interventions: Drug: Regorafenib 40 MG; Drug: Regorafenib 20MG; Drug: Nivolumab
Sponsor: Sarcoma Alliance for Research through Collaboration
Recruiting -
Remote Ischemic Conditioning in Oncology
Posted: March 18th, 2021, 2:00pm GMT
Condition: Participants Undergoing Anthracycline Chemotherapy
Intervention: Device: autoRIC®
Sponsor: Children's Hospital Medical Center, Cincinnati
Recruiting -
Study of Adoptive Immunotherapy in Relapsed and Non-resectable Sarcomas After Multimodal Treatment.
Posted: March 17th, 2021, 2:00pm GMT
Condition: Sarcoma
Intervention: Drug: Autologous CIK
Sponsor: Prof. Franca Fagioli
Recruiting -
Efficacy of Spartalizumab Across Multiple Cancer-types in Patients With PD1-high mRNA Expressing Tumors
Posted: March 17th, 2021, 2:00pm GMT
Conditions: MSI-H Colorectal Cancer; Melanoma; Anal Carcinoma; Mesothelioma; Triple Negative Breast Cancer; Lung Adenocarcinoma; Cholangiocarcinoma; Cervical Carcinoma; Kidney Clear Cell Carcinoma; Stomach Adenocarcinoma; Esophageal Adenocarcinoma; Uterine Endometrial Carcinoma; Head and Neck Squamous Cell Carcinoma; Sarcoma; Lung Squamous Cell Carcinoma; Bladder Carcinoma; Thyroid Carcinoma; Hepatocellular Carcinoma; Uveal Melanoma; HER2-positive Breast Cancer; Pancreatic Adenocarcinoma; Squamous Esophageal Carcinoma; Ovarian Serous Cystadenocarcinoma; Uterine Carcinosarcoma; Small Cell Lung Cancer; Hormone Receptor Positive / HER2-negative Breast Cancer; Lung Adenocarcinoma EGFR-mutated/ ALK Traslocation; Colorectal Adenocarcinoma; Prostate Adenocarcinoma; Carcinoma of Unknown Primary; Other Histology
Intervention: Drug: Spartalizumab
Sponsors: SOLTI Breast Cancer Research Group; Novartis
Recruiting -
Study on Trabectedin in Combination With Pioglitazone in Patients Myxoid Liposarcomas With Stable Disease After T Alone.
Posted: March 11th, 2021, 3:00pm GMT
Conditions: Liposarcoma, Myxoid; Liposarcoma, Dedifferentiated; Liposarcoma, Round Cell
Interventions: Drug: Trabectedin; Drug: Pioglitazone Oral Product
Sponsors: Mario Negri Institute for Pharmacological Research; Fondazione IRCCS Istituto Nazionale dei Tumori, Milano; Humanitas Hospital, Italy
Not yet recruiting -
A Pilot Study of Thermodox and MR-HIFU for Treatment of Relapsed Solid Tumors
Posted: March 10th, 2021, 3:00pm GMT
Conditions: Solid Tumors; Soft Tissue Sarcoma; Ewing Sarcoma; Malignant Epithelial Neoplasm; Rhabdomyosarcoma; Wilms Tumor; Hepatic Tumor; Germ Cell Tumor; Bone Metastases
Interventions: Device: Magnetic Resonance-Guided High Intensity Focused Ultrasound; Drug: Lyso-thermosensitive Liposomal Doxorubicin
Sponsor: Children's National Research Institute
Not yet recruiting -
Lenvatinib and Pembrolizumab in People With Advanced Soft Tissue Sarcoma
Posted: March 5th, 2021, 3:00pm GMT
Condition: Advanced Sarcoma
Interventions: Drug: Lenvatinib; Drug: Pembrolizumab
Sponsors: Memorial Sloan Kettering Cancer Center; Merck Sharp & Dohme Corp.; Parker Institute for Cancer Immunotherapy
Recruiting -
APG-115 in Combination With PD-1 Inhibitor in Patients With Advanced Liposarcoma or Advanced Solid Tumors
Posted: March 5th, 2021, 3:00pm GMT
Conditions: Liposarcoma; Advanced Solid Tumor
Interventions: Drug: APG-115; Drug: Toripalimab
Sponsors: Ascentage Pharma Group Inc.; Suzhou Yasheng Pharmaceutical Co., Ltd.
Recruiting -
A 3 Arm Randomized Study on Health-related QoL of Elderly Patients With Advanced Soft Tissue Sarcoma
Posted: March 3rd, 2021, 3:00pm GMT
Condition: Advanced Soft-tissue Sarcoma
Interventions: Drug: Doxorubicin; Drug: Cyclophosphamide Oral Product; Drug: Prednisolone
Sponsor: European Organisation for Research and Treatment of Cancer - EORTC
Not yet recruiting -
A Clinical Study of T3011 When Administered Via Intravenous Infustion in Patients With Advanced or Metastatic Solid Tumors
Posted: March 3rd, 2021, 3:00pm GMT
Conditions: Head and Neck Cancer; Soft Tissue Tumor and/or Sarcoma; Neoplasm of Skin; Neoplasm Metastasis; Melanoma; Nsclc; Metastasis in Lung; Metastasis in Liver; Solid Tumor
Interventions: Biological: T3011; Combination Product: T3011+Pembrolizumab
Sponsor: ImmVira Pharma Co. Ltd
Not yet recruiting -
Sequential Neoadjuvant Chemotherapy in Soft Tissue Sarcoma
Posted: March 1st, 2021, 3:00pm GMT
Condition: Soft Tissue Sarcoma
Interventions: Drug: Ifosfamide; Drug: Doxorubicin
Sponsors: Oslo University Hospital; Haukeland University Hospital
Recruiting -
Efficacy and Safety of Different Concentrations of Sirolimus in the Treatment of Kaposiform Hemangioendothelioma.
Posted: March 1st, 2021, 3:00pm GMT
Condition: Kaposiform Hemangioendothelioma
Intervention: Drug: Sirolimus
Sponsor: West China Hospital
Recruiting -
Molecular Characterization of Genetic Alterations in Pediatric Solid Tumors
Posted: February 26th, 2021, 3:00pm GMT
Condition: Pediatric Solid Tumors
Intervention:
Sponsor: National Council of Scientific and Technical Research, Argentina
Recruiting -
Avapritinib for the Treatment of CKIT or PDGFRA Mutation-Positive Locally Advanced or Metastatic Malignant Solid Tumors
Posted: February 25th, 2021, 3:00pm GMT
Conditions: Anatomic Stage IV Breast Cancer AJCC v8; Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8; Clinical Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8; Clinical Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8; Locally Advanced Malignant Solid Neoplasm; Locally Advanced Melanoma; Locally Advanced Primary Malignant Central Nervous System Neoplasm; Locally Advanced Sarcoma; Metastatic Malignant Solid Neoplasm; Metastatic Melanoma; Metastatic Primary Malignant Central Nervous System Neoplasm; Metastatic Sarcoma; Pathologic Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8; Pathologic Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8; Pathologic Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8; Postneoadjuvant Therapy Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8; Postneoadjuvant Therapy Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8; Postneoadjuvant Therapy Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8; Prognostic Stage IIIC Breast Cancer AJCC v8; Prognostic Stage IV Breast Cancer AJCC v8; Stage IIIC Colorectal Cancer AJCC v8; Stage IIIC Lung Cancer AJCC v8; Stage IV Colorectal Cancer AJCC v8; Stage IV Lung Cancer AJCC v8; Stage IVA Colorectal Cancer AJCC v8; Stage IVA Lung Cancer AJCC v8; Stage IVB Colorectal Cancer AJCC v8; Stage IVB Lung Cancer AJCC v8; Stage IVC Colorectal Cancer AJCC v8
Intervention: Drug: Avapritinib
Sponsors: M.D. Anderson Cancer Center; National Cancer Institute (NCI)
Recruiting -
TAS-117 in Patients With Advanced Solid Tumors Harboring Germline PTEN Mutations
Posted: February 25th, 2021, 3:00pm GMT
Conditions: Advanced or Metastatic Solid Tumors Irrespective of Gene Alterations; Advanced or Metastatic Solid Tumors With Germline PTEN Inactivating Mutations
Intervention: Drug: TAS-117
Sponsor: Taiho Oncology, Inc.
Recruiting -
A Study to Evaluate the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of ION363 in Amyotrophic Lateral Sclerosis Participants With Fused in Sarcoma Mutations (FUS-ALS)
Posted: February 24th, 2021, 3:00pm GMT
Condition: Amyotrophic Lateral Sclerosis
Interventions: Drug: ION363; Drug: Placebo
Sponsor: Ionis Pharmaceuticals, Inc.
Recruiting -
Pegylated Liposomal Doxorubicin Combined With Anlotinib for Neoadjuvant Treatment of Soft Tissue Sarcoma
Posted: February 22nd, 2021, 3:00pm GMT
Condition: Stage III Adult Soft Tissue Sarcoma
Interventions: Drug: Pegylated liposomal doxorubicin; Drug: Anlotinib
Sponsor: Yong Chen
Recruiting -
Metformin as Maintenance Therapy in Patients With Bone Sarcoma and High Risk of Relapse
Posted: February 17th, 2021, 3:00pm GMT
Conditions: Osteosarcoma; Ewing Sarcoma
Intervention: Drug: Metformin Hydrochloride
Sponsor: Istituto Ortopedico Rizzoli
Recruiting -
Comparison of Oral Cyclophosphamide vs Doxorubicin in ≥65 Years Old Advanced or Metastatic Soft Tissue Sarcoma Patients
Posted: February 17th, 2021, 3:00pm GMT
Conditions: Advanced Soft-tissue Sarcoma; Metastatic Soft-tissue Sarcoma
Interventions: Drug: Doxorubicin; Drug: Cyclophosphamide
Sponsor: UNICANCER
Recruiting -
The Sarcoma Biology and Outcome Project
Posted: February 17th, 2021, 3:00pm GMT
Conditions: Sarcoma; Malignant Mesenchymoma; Sarcoma of Bone and Connective Tissue
Intervention:
Sponsor: Prof. Dr. Richard F Schlenk
Recruiting -
Efficacy of Exercise Program on Osteosarcoma Patients
Posted: February 16th, 2021, 3:00pm GMT
Condition: Osteosarcoma
Intervention: Other: standard rehabilitation protocol
Sponsor: Cairo University
Not yet recruiting -
Evaluating the Impact of Limited Compared With Intense Post-Operative Surveillance on Patient-Reported Outcomes in Patients With Stage III-IV Soft Tissue Sarcoma of the Trunk and Extremities
Posted: February 12th, 2021, 3:00pm GMT
Conditions: Stage II Soft Tissue Sarcoma of the Trunk and Extremities AJCC v8; Stage III Soft Tissue Sarcoma of the Trunk and Extremities AJCC v8; Stage IIIA Soft Tissue Sarcoma of the Trunk and Extremities AJCC v8; Stage IIIB Soft Tissue Sarcoma of the Trunk and Extremities AJCC v8
Interventions: Procedure: Chest Radiography; Procedure: Computed Tomography; Procedure: Follow-Up; Procedure: Imaging Technique; Other: Questionnaire Administration
Sponsor: M.D. Anderson Cancer Center
Recruiting -
Intraoperative Tumor Margin Identification With ICG Dye Imaging
Posted: February 12th, 2021, 3:00pm GMT
Conditions: Benign Neoplasm; Malignant Neoplasm
Interventions: Drug: Indocyanine green; Device: SPY-PHI
Sponsor: Massachusetts General Hospital
Not yet recruiting -
Testing the Combination of Two Immunotherapy Drugs (Magrolimab and Dinutuximab) in Patients With Relapsed or Refractory Neuroblastoma or Relapsed Osteosarcoma
Posted: February 12th, 2021, 3:00pm GMT
Conditions: High Risk Neuroblastoma; Recurrent Neuroblastoma; Recurrent Osteosarcoma; Refractory Neuroblastoma; Resectable Osteosarcoma
Interventions: Biological: Dinutuximab; Biological: Magrolimab; Procedure: Resection
Sponsor: National Cancer Institute (NCI)
Not yet recruiting -
A Study of BPM31510 With Vitamin K1 in Subjects With Newly Diagnosed Glioblastoma (GB)
Posted: February 12th, 2021, 3:00pm GMT
Conditions: Glioblastoma; Glioblastoma Multiforme
Interventions: Drug: BPM31510; Other: Vitamin K1; Drug: Temozolomide (TMZ); Radiation: Radiation
Sponsor: Berg, LLC
Not yet recruiting -
Study on Clinical Features and Outcomes of Breast Sarcoma
Posted: February 11th, 2021, 3:00pm GMT
Condition: Breast Sarcoma
Intervention: Other: Treatment of Breast Sarcoma according clinical practice (includes drugs, surgery or any other received treatments)
Sponsor: Italian Sarcoma Group
Recruiting -
Study of TT-00420 Tablet as Monotherapy and Combination Therapy in Patients With Advanced Solid Tumors
Posted: February 8th, 2021, 3:00pm GMT
Conditions: Advanced Solid Tumor; Cholangiocarcinoma; HER2-negative Breast Cancer; Triple Negative Breast Cancer; Bladder Cancer; Small-cell Lung Cancer; Prostate Cancer; Thyroid Cancer; Sarcoma; Gastric Cancer; Gallbladder Cancer
Interventions: Drug: TT-00420; Combination Product: Nab-Paclitaxel
Sponsor: TransThera Biosciences Co., Ltd
Not yet recruiting -
Efficacy of the Combination of Nivolumab and Ipilimumab as a Treatment in Patients With Sarcoma of Rare Subtype
Posted: February 5th, 2021, 3:00pm GMT
Condition: Sarcoma
Interventions: Drug: Nivolumab and IPILIMUMAB; Drug: Pazopanib Oral Tablet [Votrient]
Sponsor: Centre Leon Berard
Recruiting -
Study of LM-102 in Subjects in Advanced Tumors
Posted: February 3rd, 2021, 3:00pm GMT
Condition: Advanced Solid Tumors
Intervention: Drug: Drug：LM-102
Sponsor: LaNova Medicines Limited
Recruiting -
A Clinical Trial Assessing BT-001 Alone and in Combination With Pembrolizumab in Metastatic or Advanced Solid Tumors
Posted: January 26th, 2021, 3:00pm GMT
Conditions: Solid Tumor, Adult; Metastatic Cancer; Soft Tissue Sarcoma; Merkel Cell Carcinoma; Melanoma; Triple Negative Breast Cancer; Non Small Cell Lung Cancer
Interventions: Biological: BT-001; Biological: Pembrolizumab [Keytruda]
Sponsors: Transgene; BioInvent International AB
Recruiting -
Fluorescent Intra-operative Tumor Margin Examination
Posted: January 22nd, 2021, 3:00pm GMT
Condition: Sarcoma
Interventions: Drug: Indocyanine green solution administered at 2.5mg/kg.; Device: Stryker SPY-PHI Imaging Device
Sponsors: Kurt Weiss; Stryker Nordic
Recruiting -
Treatment of Early Hypertension Among Persons Living With HIV in Haiti
Posted: December 31st, 2020, 3:00pm GMT
Conditions: HIV/AIDS; Pre Hypertension
Intervention: Drug: Amlodipine 5mg
Sponsors: Weill Medical College of Cornell University; Haitian Group for the Study of Kaposi's Sarcoma and Opportunistic; Fogarty International Center of the National Institute of Health
Recruiting -
Oleclumab and Durvalumab for the Treatment of Recurrent, Refractory, or Metastatic Sarcoma
Posted: December 16th, 2020, 3:00pm GMT
Conditions: Metastatic Angiosarcoma; Metastatic Dedifferentiated Liposarcoma; Metastatic Osteosarcoma; Recurrent Angiosarcoma; Recurrent Dedifferentiated Liposarcoma; Recurrent Osteosarcoma; Refractory Dedifferentiated Liposarcoma; Refractory Osteosarcoma
Interventions: Biological: Durvalumab; Biological: Oleclumab
Sponsors: M.D. Anderson Cancer Center; National Cancer Institute (NCI)
Recruiting -
Length of the Femoral Stem in Arthroplasty Done for Patients With Proximal Femoral Metastatic Lesion
Posted: December 9th, 2020, 3:00pm GMT
Conditions: Metastatic Bone Tumor; Pathological Fracture; Arthroplasty
Intervention: Device: femoral stem in hip arthroplasty
Sponsor: Ain Shams University
Recruiting -
A Home-Based Approach Study to Evaluate the Efficacy and Safety of Alectinib in Locally-Advanced or Metastatic ALK-Positive Solid Tumors
Posted: November 25th, 2020, 3:00pm GMT
Condition: Solid Tumors
Intervention: Drug: Alectinib
Sponsor: Hoffmann-La Roche
Recruiting -
Heat Shock Protein (HSP) 70 to Quantify and Characterize Circulating Tumor Cells
Posted: November 16th, 2020, 3:00pm GMT
Conditions: Melanoma Stage IV; Sarcoma; Squamous Cell Carcinoma; Pancreatic Cancer Stage IV; Prostate Cancer; Breast Cancer Stage IV
Intervention: Diagnostic Test: CTC isolation by HSP70
Sponsors: Charite University, Berlin, Germany; Klinikum rechts der Isar, TU München, (TUM), Munich, Germany.
Recruiting -
A Study of Rucaparib and Nivolumab in People With Leiomyosarcoma
Posted: November 10th, 2020, 3:00pm GMT
Condition: Leiomyosarcoma
Interventions: Drug: Rucaparib; Drug: Nivolumab
Sponsors: Memorial Sloan Kettering Cancer Center; Bristol-Myers Squibb; Clovis Oncology, Inc.
Recruiting -
First-in-man Clinical Trial of CEB-01 PLGA Membrane in Recurrent or Locally Advanced Retroperitoneal Soft Tissue Sarcoma
Posted: November 6th, 2020, 3:00pm GMT
Conditions: Locally Advanced Soft Tissue Sarcoma; Recurrent Soft Tissue Sarcoma
Intervention: Combination Product: CEB-01 membrane loaded with SN-38
Sponsor: CEBIOTEX
Recruiting -
Augmented Reality (AR): The Future of "Patient Information Leaflets
Posted: November 6th, 2020, 3:00pm GMT
Conditions: Sarcoma; Breast Cancer; Cleft Lip and Palate; Surgical Flap
Interventions: Other: Augmented Reality; Other: Traditional leaflet
Sponsors: NHS Greater Glasgow and Clyde; The Glasgow School of Art
Recruiting -
Pemetrexed, Cisplatin With Soft Tissue Sarcoma
Posted: October 28th, 2020, 2:00pm GMT
Condition: Sarcoma,Soft Tissue
Intervention: Drug: pemetrexed+cisplatin
Sponsor: Yonsei University
Recruiting -
Study in Low Risk Gastrointestinal Stromal Tumor (GISTs)
Posted: October 23rd, 2020, 2:00pm GMT
Condition: GIST
Intervention: Other: Treatment of Low Risk GISTs according clinical practice (includes drugs, surgery or any other received treatments)
Sponsor: Italian Sarcoma Group
Recruiting -
Testing the Anti-cancer Drug, Rogaratinib (BAY 1163877), for Treatment of Advanced Sarcoma With Alteration in Fibroblast Growth Factor Receptor (FGFR 1-4), and in Patients With SDH-deficient Gastrointestinal Stromal Tumor (GIST)
Posted: October 22nd, 2020, 2:00pm GMT
Conditions: Gastrointestinal Stromal Tumor; Recurrent Sarcoma
Intervention: Drug: Rogaratinib
Sponsor: National Cancer Institute (NCI)
Recruiting -
TVEC and Preop Radiation for Sarcoma (8 ml Dose)
Posted: October 22nd, 2020, 2:00pm GMT
Condition: Soft Tissue Sarcoma
Interventions: Drug: Talimogene Laherparepvec; Radiation: Radiotherapy
Sponsors: Varun Monga, MD; Amgen
Recruiting -
CDK4/6 Tumor, Abemaciclib, Paclitaxel
Posted: October 20th, 2020, 2:00pm GMT
Condition: Tumors
Intervention: Drug: abemaciclib+paclitaxel
Sponsor: Yonsei University
Recruiting -
Tumor-Agnostic Precision Immuno-Oncology and Somatic Targeting Rational for You (TAPISTRY) Platform Study
Posted: October 19th, 2020, 2:00pm GMT
Condition: Solid Tumors
Interventions: Drug: Entrectinib; Drug: Alectinib; Drug: Atezolizumab; Drug: Ipatasertib; Drug: Trastuzumab emtansine; Drug: Idasanutlin; Drug: Inavolisib; Drug: Belvarafenib; Drug: Pralsetinib
Sponsor: Hoffmann-La Roche
Recruiting -
Adriamycin and Ifosfamide Combined With Sintilimab
Posted: October 19th, 2020, 2:00pm GMT
Condition: Soft Tissue Sarcoma
Intervention: Drug: Sintilimab plus chemotherapy
Sponsor: Sun Yat-sen University
Not yet recruiting -
Toripalimab Combined With CAV / IE Regimen
Posted: October 19th, 2020, 2:00pm GMT
Condition: Soft Tissue Sarcoma
Intervention: Drug: Toripalimab Combined With CAV / IE Regimen chemotherapy
Sponsor: Sun Yat-sen University
Recruiting -
Surufatinib in Combination With Tislelizumab in Subjects With Advanced Solid Tumors
Posted: October 8th, 2020, 2:00pm GMT
Conditions: Metastatic Solid Tumor; Colorectal Cancer; Neuroendocrine Tumors; Small Cell Lung Cancer; Gastric Cancer; Soft Tissue Sarcoma
Interventions: Drug: Surufatinib and Tislelizumab _ Part 1; Drug: Surufatinib and Tislelizumab _ Part 2
Sponsors: Hutchison Medipharma Limited; BeiGene
Recruiting -
Pomalidomide Treatment in Patients With Kaposi Sarcoma
Posted: October 8th, 2020, 2:00pm GMT
Condition: Skin Kaposi Sarcoma
Intervention: Drug: Pomalidomide
Sponsor: National Cancer Institute (NCI)
Not yet recruiting -
Study to Test the Safety and Tolerability of PF-07220060 in Participants With Advance Solid Tumors
Posted: September 21st, 2020, 2:00pm GMT
Conditions: Liposarcoma; CRC; Prostate Cancer; Breast Neoplasms; Adenocarcinoma of Lung; Solid Tumors
Interventions: Drug: PF-07220060; Combination Product: Letrozole; Combination Product: Fulvestrant
Sponsor: Pfizer
Recruiting -
Anti-PD-L1 Armored Anti-CD22 CAR-T/CAR-TILs Targeting Patients With Solid Tumors
Posted: September 21st, 2020, 2:00pm GMT
Conditions: Solid Tumor, Adult; Cervical Cancer; Sarcoma; NSCLC
Intervention: Biological: Autologous aPD-L1 armored anti-CD22 CAR T cells
Sponsor: Hebei Senlang Biotechnology Inc., Ltd.
Recruiting -
A Study to Evaluate Tabelecleucel in Participants With Epstein-barr Virus-associated Diseases
Posted: September 18th, 2020, 2:00pm GMT
Conditions: Epstein-Barr Virus (EBV)-Associated Diseases; EBV+ Lymphoproliferative Disease With Primary Immunodeficiency (PID LPD); EBV+ Lymphoproliferative Disease With Acquired (Non-congenital) Immunodeficiency (AID LPD); EBV+ Posttransplant Lymphoproliferative Disease in Central Nervous System (CNS PTLD); EBV+ Post-transplant Lymphoproliferative Disease (EBV+ PTLD); Solid Organ Transplant Complications; Lymphoproliferative Disorders; Allogeneic Hematopoietic Cell Transplant; Stem Cell Transplant Complications; EBV+ Sarcomas; Leiomyosarcoma; Chronic Active Epstein-Barr Virus (CAEBV); Chronic Active Epstein-Barr Virus With Hemophagocytic Lymphohistiocytosis (HLH); Lymphohistiocytosis, Hemophagocytic
Intervention: Biological: Tabelecleucel
Sponsor: Atara Biotherapeutics
Recruiting -
MoLiMoR - A Study With FOLFIRI-based First-line Therapy With or Without Intermittent Cetuximab
Posted: September 18th, 2020, 2:00pm GMT
Conditions: Adenocarcinoma of the Colon; Adenocarcinoma of the Rectum
Interventions: Drug: Cetuximab; Other: FOLFIRI
Sponsor: TheraOp
Recruiting